While Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) In Russell 3000® and Russell Microcap® Indexes, Inpixon (NASDAQ: INPX) Included In The Russell Microcap® Index

June 30, 2021

Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX), a clinical-stage biotechnology company involved in developing allogeneic cell therapies for unmet medical needs, in an official statement, announced that the company had made it to broad-market Russell 3000® Index as well as the Russell Microcap® Index. Inpixon (NASDAQ: INPX) included in Russell Microcap® Index Inpixon (NASDAQ: INPX), the Indoor Intelligence™ company, announced that it had made it to the Russell Microcap® Index. By…

Read More >>

Lineage Cell Therapeutics Inc. (NYSEAMERICAN: LCTX) Gains After FDA Gives Feedback On OPC1 IND

June 29, 2021

Lineage Cell Therapeutics Inc. (NYSEAMERICAN: LCTX) gained 2.16% after releasing an update in OPC1’s clinical development. OPC1 is the company’s experimental allogeneic oligodendrocyte progenitor cell (OPC) transplant therapy for spinal cord injury treatment.  Lineage receives FDA feedback on OPC1 IND Last week the company received feedback from the FDA under the US FDA’s Regenerative Medicine Advanced Therapy program. As a result, Lineage is planning to submit an amendment to its…

Read More >>

Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) Brings Onboard Kevin Cook To Serve As The Company’s Chief Financial Officer

June 25, 2021

Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) is quite pleased to make Kevin Cook its new Chief Financial Officer, effective June 21, 2021. It believes that the official will greatly contribute to its efforts to grow and become a top cell therapy and cell Transplant Company. The company considered Cook’s qualifications and track record The company chose Cook after considering the value he would bring to its business. That starts with his…

Read More >>